- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04103476
Advancing Postmenopausal Preventive Therapy (APPT)
June 30, 2022 updated by: Howard N. Hodis, MD, University of Southern California
Atherosclerosis Intervention With Novel Tissue Selective Estrogen Complex Therapy
Advancing Postmenopausal Preventive Therapy (APPT) is a randomized, double-blinded, placebo-controlled trial designed to determine the effects of tissue selective estrogen complex (TSEC) therapy on the progression of subclinical atherosclerosis and cognitive decline in 360 healthy postmenopausal women.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
To conduct a double-blinded, placebo-controlled trial to determine the effects of TSEC therapy on the progression of subclinical atherosclerosis in healthy postmenopausal women.
A total of 360 postmenopausal women with a uterus who are within 6 years of menopause and 45-59 years of age and without clinical cardiovascular disease and diabetes mellitus will be randomized to Bazedoxifene/Conjugated Equine Estrogen (BZA 20 mg/CE 0.45 mg) or placebo.
Recruitment will occur over 3 years and the treatment period will be up to 3 years depending on when an individual is randomized.
Rate of change in carotid artery intima-media thickness (CIMT) determined from the distal common carotid artery (CCA) far wall intima-media thickness (IMT) in computer image processed B mode ultrasonograms will be the primary trial endpoint.
Arterial stiffness measured from the CCA (same location as CIMT) in computer image processed B mode ultrasonograms will be the secondary trial endpoint.
Three composite cognitive measures will be used to test for randomized treatment group differences in cognition; each composite will be considered as co-endpoints.
Study Type
Interventional
Enrollment (Anticipated)
400
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lora Maxwell, RN
- Phone Number: (323) 442-2257
- Email: APPT@usc.edu
Study Contact Backup
- Name: Janie Teran
- Phone Number: (323) 442-1478
- Email: athero@usc.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Recruiting
- University of Southern California Atherosclerosis Research Unit
-
Contact:
- Lora Maxwell, RN
- Phone Number: 323-442-2257
- Email: APPT@usc.edu
-
Contact:
- Janie Teran
- Phone Number: 323-442-1478
- Email: athero@usc.edu
-
Principal Investigator:
- Howard N. Hodis, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 59 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women with a serum estradiol level <30 pg/ml and cessation of regular menses >6 months who are <6 years postmenopausal and 45-59 years old.
Exclusion Criteria:
- Women with a hysterectomy
- Clinical signs, symptoms or personal history of cardiovascular disease
- Diabetes mellitus or fasting serum glucose >126 mg/dL
- Life threatening illness with prognosis <5 years
- Cirrhosis or liver disease
- History of deep vein thrombosis or pulmonary embolism
- History of breast cancer
- Current use of postmenopausal hormone replacement therapy (HRT) within 1 month of randomization
- Uncontrolled hypertension (>180/>110 mmHg)*
- Plasma triglyceride levels >500 mg/dL
- Serum creatinine >2.0 mg/dL
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BZA/CE
Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
|
Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
|
Placebo Comparator: Placebo
Oral matching placebo
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Carotid artery intima-media thickness
Time Frame: At baseline and 6 months, 1 year, 1.5 years, 2 years, 2.5 years and 3 years after randomization
|
Rate of change in carotid artery intima-media thickness (CIMT) determined from the distal common carotid artery (CCA) far wall intima-media thickness (IMT) in computer image processed B mode ultrasonograms.
|
At baseline and 6 months, 1 year, 1.5 years, 2 years, 2.5 years and 3 years after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CCA stiffness
Time Frame: At baseline and 6 months, 1 year, 1.5 years, 2 years, 2.5 years and 3 years after randomization
|
Arterial stiffness measured from the CCA (same location as CIMT) in computer image processed B mode ultrasonograms.
|
At baseline and 6 months, 1 year, 1.5 years, 2 years, 2.5 years and 3 years after randomization
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive decline
Time Frame: At baseline and 6 months, 1 year, 1.5 years, 2 years, 2.5 years and 3 years after randomization
|
Three composite cognitive measures will be used to test for randomized treatment group differences in cognition; each composite will be considered as co-endpoints.
|
At baseline and 6 months, 1 year, 1.5 years, 2 years, 2.5 years and 3 years after randomization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Howard N. Hodis, MD, University of Southern California Atherosclerosis Research Unit
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 13, 2021
Primary Completion (Anticipated)
October 31, 2026
Study Completion (Anticipated)
December 31, 2026
Study Registration Dates
First Submitted
September 20, 2019
First Submitted That Met QC Criteria
September 23, 2019
First Posted (Actual)
September 25, 2019
Study Record Updates
Last Update Posted (Actual)
July 5, 2022
Last Update Submitted That Met QC Criteria
June 30, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Neurocognitive Disorders
- Cognition Disorders
- Cognitive Dysfunction
- Atherosclerosis
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Bone Density Conservation Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Bazedoxifene
- Estrogens
- Estrogens, Conjugated (USP)
Other Study ID Numbers
- R01AG058691 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Central Hospital, Nancy, FranceSuspended
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
-
Emory UniversityThe Robert W. Woodruff FoundationCompleted
-
Korea UniversityMinistry of Health & Welfare, KoreaCompletedAtherosclerosis | Noninvasive Imaging of AtherosclerosisKorea, Republic of
-
Zhejiang Zylox Medical Device Co., Ltd.RecruitingAtherosclerosis of Femoral ArteryGermany
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States